British Virgin Islands vs Cayman Islands: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
British Virgin Islands
0.2%
in 2024
Cayman Islands
0.2%
in 2024
British Virgin Islands rank
98th
Cayman Islands rank
98th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- British Virgin Islands
- Cayman Islands
How they compare
British Virgin Islands currently reports 0.2% against 0.2% in Cayman Islands, a difference of 0.0%.
Across all 10 years both countries report, Cayman Islands has been ahead every year.
British Virgin Islands ranks 98th and Cayman Islands ranks 98th of 246 countries.
Head to head by decade
| Decade | British Virgin Islands | Cayman Islands | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | — |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, British Virgin Islands or Cayman Islands?
- British Virgin Islands, at 0.2% against 0.2% in Cayman Islands as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between British Virgin Islands and Cayman Islands?
- 0.0%, with British Virgin Islands ahead.
- How many years of comparable data are there for British Virgin Islands and Cayman Islands?
- 10 years are reported by both, from 2015 to 2024.
- How do British Virgin Islands and Cayman Islands rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- British Virgin Islands ranks 98th and Cayman Islands ranks 98th of 246 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.